Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 19/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760828 | 1.00 | SLC40A1 (0.59) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL31257251 | 1.00 | SLC40A1 (0.59) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL7074716 | 0.92 | SLC40A1 (0.63) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL6886824 | 0.91 | CXCR4 (0.55) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| Bromide SCHEMBL7074322 | 0.91 | SLC40A1 (0.62) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL5671385 | 0.90 | SLC40A1 (0.62) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL6886947 | 0.90 | SLC40A1 (0.62) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL4761648 | 0.90 | SLC40A1 (0.62) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL3406461 | 0.89 | CXCR4 (0.56) | SLC40A1CXCR4CHRM2CYP2D6DRD2 | |
| SCHEMBL5106464 | 0.89 | SLC40A1 (0.57) | SLC40A1CXCR4CHRM2CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216095-A1 | SYNTHESIS OF MAVORIXAFOR AND INTERMEDIATES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | SLC40A1 2690/4885CXCR4 9/4885CHRM2 882/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | SLC40A1 2231/4885CXCR4 2/4885CHRM2 2757/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | SLC40A1 2231/4885CXCR4 2/4885CHRM2 2757/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | SLC40A1 3582/4885CXCR4 7/4885CHRM2 1305/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | SLC40A1 2231/4885CXCR4 2/4885CHRM2 2757/4885 |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | SLC40A1 2231/4885CXCR4 2/4885CHRM2 2757/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | SLC40A1 2231/4885CXCR4 2/4885CHRM2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.